The opening price for Equinix, Inc. (NASDAQ:EQIX) was $461.37 and the volume amounted to 0.3 million shares which compares with the average volume of 0.44 million shares. The company stock experienced a 0.91% move to arrive at $462.97.Equinix, Inc. (EQIX) Analyst Opinion
Equinix, Inc. has a consensus outperform rating from 24 Wall Street analysts, and the number of shares currently sold short amount to at least 2.55% of shares outstanding. The stock spiked 5.89% last month and is up 29.53 this year. Wall Street is only getting more bullish on the stock, with 19 of analysts who cover EQIX having a buy-equivalent rating. Analysts have placed a $500.71 price target on Equinix, Inc., suggesting a 8.15% gain from recent close. It’s currently trading about -2.59% below its 52-week high.
Equinix, Inc. (EQIX) failed to surprise the stock market in its last reported earnings when it earned $0.58 a piece versus the consensus-estimated $1.07. Its revenue totaled $1.06 billion up 11.71% from the previous quarter.Equinix, Inc. (NASDAQ:EQIX) Intraday View
This stock (EQIX) is ahead of its 52-week low with 47.18%. Its last month’s stock price volatility remained 1.65% which for the week stands at 1.5%. The share price has moved forward from its 20 days moving average, trading at a distance of 2.08% and stays 1.55% away from its 50 days moving average. Over the last five days, shares have managed 0.3% gains and now is up 9.82% since hitting its 200-day moving average of $439.77. Equinix, Inc. (EQIX) has made its way to a 12-month gain of 24.42%.
Turning to Sorrento Therapeutics, Inc. (NASDAQ:SRNE), its shares were trading at $2.6 a retreat of $0, on the trading floor. The stock, after opening at $2.65, touched a high of $2.8 before paring much of its gains. So far, analysts are sticking with their bullish recommendations with the consensus call at 1.5. Sorrento Therapeutics, Inc. has 1 buy ratings, 0 holds and 0 sells even after the stock tumbled -62.94% from its high of $ 6.60 to a $182.29 million market value through last close.
The company’s consensus rating on Reuter’s scale remained unchanged from 1.5 to 1.5 during a month. Analysts set a 12-month price target of $13.5 a share. The target implies a 419.23% spike from where the shares are currently trading. Also, the current price highlights a discount of 669.23% to analysts’ high consensus price target.Sorrento Therapeutics, Inc. (NASDAQ:SRNE) Intraday Trading
The counter witnessed a trading volume of 0.97 million shares versus an average volume of 1.06 million shares during last trading session. Its last month’s stock price volatility remained 12.61% which for the week approaches 14.75%. The lowest price the stock reached in the last trading day was $2.5 and compares with the $1.50 52-week low. The stock recovered 73.33% since its low point and has performed -46.94% year-to-date.